CFM-2

Pricing Availability Delivery Time Qty
Cat.No. 1082 - CFM-2 | C17H17N3O3 | CAS No. 178616-26-7
Description: Non-competitive AMPA antagonist
Chemical Name: 1-(4'-Aminophenyl)-3,5-dihydro-7,8-dimethoxy-4H-2,3-benzodiazepin-4-one
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Literature

Biological Activity

Novel, selective non-competitive AMPA antagonist. Highly potent, long-acting anticonvulsant.

Technical Data

M. Wt 311.34
Formula C17H17N3O3
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 178616-26-7
PubChem ID 4377504
InChI Key MJKADKZSYQWGLL-UHFFFAOYSA-N
Smiles COC1=CC2=C(C=C1OC)C(=NNC(=O)C2)C1=CC=C(N)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 31.13 100

Preparing Stock Solutions

The following data is based on the product molecular weight 311.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.21 mL 16.06 mL 32.12 mL
5 mM 0.64 mL 3.21 mL 6.42 mL
10 mM 0.32 mL 1.61 mL 3.21 mL
50 mM 0.06 mL 0.32 mL 0.64 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the products' biological activity.

Chimirri et al (1997) 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J.Med.Chem. 40 1258 PMID: 9111300

De Sarro et al (1999) Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur.J.Pharmacol. 368 149 PMID: 10193651

De Sarro et al (1999) Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats. Pharmacol.Biochem.Behav. 63 621 PMID: 10462191


If you know of a relevant reference for CFM-2, please let us know.

View Related Products by Target

View Related Products by Product Action

View all AMPA Receptor Antagonists

Keywords: CFM-2, supplier, Non-competitive, AMPA, antagonists, Glutamate, Receptors, iGlur, Ionotropic, AMPA, Receptors, AMPA, Receptors, Tocris Bioscience

2 Citations for CFM-2

Citations are publications that use Tocris products. Selected citations for CFM-2 include:

Rzeski et al (2001) Glutamate antagonists limit tumor growth. J Pharmacol Exp Ther 98 6372 PMID: 11331750

Nygaard et al (2015) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Proc Natl Acad Sci U S A 1 82 PMID: 25593989


Do you know of a great paper that uses CFM-2 from Tocris? If so please let us know.

CFM-2 Reviews

Average Rating:

(Based on 0 Reviews)


1 Star
0%
2 Star
0%
3 Star
0%
4 Star
0%
5 Star
0%

Have you used CFM-2?

Submit a review and receive a $25US/€18/£15/$25CAN Amazon gift card if you include an image -$10US/€7/£6/$10CAN Amazon gift card for reviews without an image. Limited to verified customers in USA, Canada and Europe.


Literature in this Area

Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.